JP2021521439A5 - - Google Patents
Info
- Publication number
- JP2021521439A5 JP2021521439A5 JP2020555862A JP2020555862A JP2021521439A5 JP 2021521439 A5 JP2021521439 A5 JP 2021521439A5 JP 2020555862 A JP2020555862 A JP 2020555862A JP 2020555862 A JP2020555862 A JP 2020555862A JP 2021521439 A5 JP2021521439 A5 JP 2021521439A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- cytokine
- composition
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862657370P | 2018-04-13 | 2018-04-13 | |
| US62/657,370 | 2018-04-13 | ||
| US201862734133P | 2018-09-20 | 2018-09-20 | |
| US62/734,133 | 2018-09-20 | ||
| US201862756496P | 2018-11-06 | 2018-11-06 | |
| US62/756,496 | 2018-11-06 | ||
| PCT/US2019/027169 WO2019200223A1 (en) | 2018-04-13 | 2019-04-12 | Cancer serum biomarkers and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521439A JP2021521439A (ja) | 2021-08-26 |
| JP2021521439A5 true JP2021521439A5 (OSRAM) | 2022-04-19 |
Family
ID=68164571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555862A Pending JP2021521439A (ja) | 2018-04-13 | 2019-04-12 | がん血清バイオマーカーおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210025895A1 (OSRAM) |
| EP (1) | EP3775877A4 (OSRAM) |
| JP (1) | JP2021521439A (OSRAM) |
| CN (1) | CN112005114A (OSRAM) |
| CA (1) | CA3095331A1 (OSRAM) |
| WO (1) | WO2019200223A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2907489T3 (es) | 2015-12-14 | 2022-04-25 | X4 Pharmaceuticals Inc | Métodos para el tratamiento del cáncer |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| HUE060517T2 (hu) | 2015-12-22 | 2023-03-28 | X4 Pharmaceuticals Inc | Immunhiányos betegség kezelésére szolgáló eljárások |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| WO2017223229A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| AU2019275404A1 (en) * | 2018-05-21 | 2020-12-03 | Bruker Spatial Biology, Inc. | Molecular gene signatures and methods of using same |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| JP2023517956A (ja) | 2020-03-10 | 2023-04-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 好中球減少症を処置する方法 |
| WO2021263115A1 (en) * | 2020-06-26 | 2021-12-30 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment |
| AU2021409465A1 (en) | 2020-12-21 | 2023-08-03 | Freenome Holdings, Inc. | Markers for the early detection of colon cell proliferative disorders |
| US12523658B2 (en) * | 2021-08-27 | 2026-01-13 | The Board Of Regents Of The University Of Texas System | Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications |
| US20230091944A1 (en) * | 2021-09-20 | 2023-03-23 | Droplet Biosciences, Inc. | Lymphatic fluid for diagnostics |
| CN114859050B (zh) * | 2022-05-30 | 2026-02-17 | 复旦大学附属肿瘤医院 | 三阴性乳腺癌免疫治疗疗效预测标志物ccl19的检测方法 |
| CN117204817A (zh) * | 2023-08-17 | 2023-12-12 | 北京肿瘤医院(北京大学肿瘤医院) | 一种血管生成抑制剂给药控制方法、装置及存储介质 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6483705B2 (en) * | 2001-03-19 | 2002-11-19 | Harris Corporation | Electronic module including a cooling substrate and related methods |
| AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
| EP3230498B1 (en) * | 2014-12-09 | 2023-01-18 | Merck Sharp & Dohme LLC | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
| EP3839510A3 (en) * | 2015-04-17 | 2021-08-25 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| EP3405203A4 (en) * | 2016-01-22 | 2019-07-24 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| WO2017177230A1 (en) * | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
-
2019
- 2019-04-12 WO PCT/US2019/027169 patent/WO2019200223A1/en not_active Ceased
- 2019-04-12 JP JP2020555862A patent/JP2021521439A/ja active Pending
- 2019-04-12 CN CN201980025714.9A patent/CN112005114A/zh active Pending
- 2019-04-12 EP EP19785850.9A patent/EP3775877A4/en not_active Withdrawn
- 2019-04-12 US US17/045,697 patent/US20210025895A1/en not_active Abandoned
- 2019-04-12 CA CA3095331A patent/CA3095331A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kroemer et al. | Immunosurveillance in clinical cancer management | |
| Nabizadeh et al. | The complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses | |
| Waldner et al. | Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development | |
| Bahig et al. | Neutrophil count is associated with survival in localized prostate cancer | |
| Rejeski et al. | Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy | |
| Xia et al. | Plasma interleukin‐37 is elevated in patients with rheumatoid arthritis: its correlation with disease activity and Th1/Th2/Th17‐related cytokines | |
| Ghanim et al. | Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis | |
| JP2021521439A (ja) | がん血清バイオマーカーおよびその使用方法 | |
| Llosa et al. | Interleukin-17 and type 17 helper T cells in cancer management and research | |
| Krzystek-Korpacka et al. | Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon | |
| Chen et al. | Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer | |
| Wubetu et al. | High STAT4 expression is a better prognostic indicator in patients with hepatocellular carcinoma after hepatectomy | |
| Wang et al. | Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade | |
| Baracco et al. | Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer | |
| Wang et al. | Cytokine profiles and the relationship of disease severity in patients with psoriasis | |
| Skipworth et al. | Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer | |
| Massari et al. | Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study | |
| Singh et al. | Idiopathic pulmonary fibrosis: where do we stand and how far to go | |
| Wang et al. | The role of IL-37 in gastrointestinal diseases | |
| Chen et al. | Correlations between serum IL33 and tumor development: a meta-analysis | |
| Rémi et al. | Pharmacological management of bronchorrhea in malignant disease: a systematic literature review | |
| Falkensammer et al. | C‐reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL‐6 in overall survival | |
| Xing et al. | Serum GDF15 level as predictive biomarker of clinical outcome in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy | |
| Culcu et al. | The effect of CEA/Albumin ratio in gastric cancer patient on prognostic factors | |
| Yang et al. | Liver metastasis of colorectal cancer: Mechanism and clinical therapy |